作者：
Carmine,De Angelis [1]
;
Xiaoyong,Fu [2]
;
Maria Letizia,Cataldo [3]
;
Agostina,Nardone [4]
;
Resel,Pereira [1]
;
Jamunarani,Veeraraghavan [3]
;
Sarmistha,Nanda [5]
;
Lanfang,Qin [1]
;
Vidyalakshmi,Sethunath [2]
;
Tao,Wang [3]
;
Susan G,Hilsenbeck [4]
;
Matteo,Benelli [6]
;
Ilenia,Migliaccio [1]
;
Cristina,Guarducci [2]
;
Luca,Malorni [3]
;
Lacey M,Litchfield [1]
;
Jiangang,Liu [2]
;
Joshua,Donaldson [3]
;
Pier,Selenica [1]
;
David N,Brown [2]
;
Britta,Weigelt [3]
;
Jorge S,Reis-Filho [1]
;
Ben H,Park [2]
;
Sara A,Hurvitz [3]
;
Dennis J,Slamon [1]
;
Mothaffar F,Rimawi [2]
;
Valerie M,Jansen [3]
;
Rinath,Jeselsohn [1]
;
C Kent,Osborne [2]
;
Rachel,Schiff [3]
作者单位：
Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas.
[1]
Department of Medicine, Baylor College of Medicine, Houston, Texas.
[2]
Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas.
[3]
Department of Clinical Medicine and Surgery, University of Naples "Federico II", Naples, Italy.
[4]
Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas.
[5]
Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
[6]
"Sandro Pitigliani" Translational Research Unit, Hospital of Prato, Prato, Italy.
[7]
"Sandro Pitigliani" Medical Oncology Department, Hospital of Prato, Prato, Italy.
[8]
Eli Lilly and Company, Indianapolis, Indiana.
[9]
Department of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee.
[10]
Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
[11]
University of California, Los Angeles, Los Angeles, California.
[12]
Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas. rschiff@bcm.edu.
[13]
DOI
10.1158/1078-0432.CCR-19-4191
PMID
33536276
发布时间
2023-02-23
换一批
换一批
